Medizinische Universität Graz - Research portal

Logo MUG Resarch Portal

Zhou Qing |

** = Publications listed in SCI/SSCI/Pubmed

2022

Full paper/article (Journal)

** Suppan, C; Graf, R; Jahn, S; Zhou, Q; Klocker, EV; Bartsch, R; Terbuch, A; Kashofer, K; Regitnig, P; Lindenmann, J; Posch, F; Gerritsmann, H; Jost, PJ; Heitzer, E; Dandachi, N; Balic, M Sensitive and robust liquid biopsy-based detection of PIK3CA mutations in hormone-receptor-positive metastatic breast cancer patients.
Br J Cancer. 2022; 126(3):456-463 Doi: 10.1038/s41416-021-01601-9 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Zhou, Q; Gampenrieder, SP; Frantal, S; Rinnerthaler, G; Singer, CF; Egle, D; Pfeiler, G; Bartsch, R; Wette, V; Pichler, A; Petru, E; Dubsky, PC; Bago-Horvath, Z; Fesl, C; Rudas, M; Ståhlberg, A; Graf, R; Weber, S; Dandachi, N; Filipits, M; Gnant, M; Balic, M; Heitzer, E Persistence of ctDNA in Patients with Breast Cancer During Neoadjuvant Treatment Is a Significant Predictor of Poor Tumor Response.
Clin Cancer Res. 2022; 28(4):697-707 Doi: 10.1158/1078-0432.CCR-21-3231 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2021

Full paper/article (Journal)

** Unseld, M; Belic, J; Pierer, K; Zhou, Q; Moser, T; Bauer, R; Piringer, G; Gerger, A; Siebenhüner, A; Speicher, M; Heitzer, E; Prager, GW A higher ctDNA fraction decreases survival in regorafenib-treated metastatic colorectal cancer patients. Results from the regorafenib's liquid biopsy translational biomarker phase II pilot study.
Int J Cancer. 2021; 148(6):1452-1461 Doi: 10.1002/ijc.33303 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Abstract (Journal)

** Suppan, C; Zhou, Q; Jahn, S; Graf, R; Klocker, EV; Terbuch, A; Kashofer, K; Posch, F; Gerritsmann, H; Dandachi, N; Heitzer, E; Balic, M Comparison of liquid biopsy and tissue based detection of PIK3CAmutations in HR positive metastatic breast cancer patients
CANCER RES. 2021; 81(4): [Poster]
Web of Science

 

2020

Full paper/article (Journal)

** Koch, C; Kuske, A; Joosse, SA; Yigit, G; Sflomos, G; Thaler, S; Smit, DJ; Werner, S; Borgmann, K; Gärtner, S; Mossahebi Mohammadi, P; Battista, L; Cayrefourcq, L; Altmüller, J; Salinas-Riester, G; Raithatha, K; Zibat, A; Goy, Y; Ott, L; Bartkowiak, K; Tan, TZ; Zhou, Q; Speicher, MR; Müller, V; Gorges, TM; Jücker, M; Thiery, JP; Brisken, C; Riethdorf, S; Alix-Panabières, C; Pantel, K Characterization of circulating breast cancer cells with tumorigenic and metastatic capacity.
EMBO Mol Med. 2020; 12(9):e11908-e11908 Doi: 10.15252/emmm.201911908 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Moser, T; Waldispuehl-Geigl, J; Belic, J; Weber, S; Zhou, Q; Hasenleithner, SO; Graf, R; Terzic, JA; Posch, F; Sill, H; Lax, S; Kashofer, K; Hoefler, G; Schoellnast, H; Heitzer, E; Geigl, JB; Bauernhofer, T; Speicher, MR On-treatment measurements of circulating tumor DNA during FOLFOX therapy in patients with colorectal cancer.
NPJ Precis Oncol. 2020; 4(1):30 Doi: 10.1038/s41698-020-00134-3 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Perakis, SO; Weber, S; Zhou, Q; Graf, R; Hojas, S; Riedl, JM; Gerger, A; Dandachi, N; Balic, M; Hoefler, G; Schuuring, E; Groen, HJM; Geigl, JB; Heitzer, E; Speicher, MR Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer.
ESMO Open. 2020; 5(5):e000872 Doi: 10.1136/esmoopen-2020-000872 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

** Zhou, Q; Perakis, SO; Ulz, P; Mohan, S; Riedl, JM; Talakic, E; Lax, S; Tötsch, M; Hoefler, G; Bauernhofer, T; Pichler, M; Gerger, A; Geigl, JB; Heitzer, E; Speicher, MR Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer.
Genome Med. 2020; 12(1):20 Doi: 10.1186/s13073-020-0719-6 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Correction

** Ulz, P; Perakis, S; Zhou, Q; Moser, T; Belic, J; Lazzeri, I; Wölfler, A; Zebisch, A; Gerger, A; Pristauz, G; Petru, E; White, B; Roberts, CES; John, JS; Schimek, MG; Geigl, JB; Bauernhofer, T; Sill, H; Bock, C; Heitzer, E; Speicher, MR Publisher Correction: Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection.
Nat Commun. 2020; 11(1): 1965-1965. Doi: 10.1038/s41467-020-15799-4 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Abstract (Journal)

** Moser, T; Waldispuehl-Geigl, J; Belic, J; Perakis, S; Weber, S; Zhou, Q; Sill, H; Lax, S; Kashofer, K; Hoefler, G; Schoellnast, H; Bauernhofer, T; Heitzer, E; Geigl, JB; Speicher, MR Early circulating tumor DNA dynamics as a real-time predictor of FOLFOX efficacy in advanced colorectal cancer patients
CANCER RES. 2020; 80(16): Doi: 10.1158/1538-7445.AM2020-4295 [Poster]
Web of Science FullText FullText_MUG

 

** Perakis, SO; Weber, S; Graf, R; Zhou, Q; Riedl, JM; Dandachi, N; Balic, M; Gerger, A; Schuuring, E; Groen, HJ; Geigl, JB; Speicher, MR; Heitzer, E Identification of actionable targets in advanced cancer patients from circulating tumor DNA using clinical decision support platforms
CANCER RES. 2020; 80(16):-AACR Annual Meeting; JUN 22-24, 2020; ELECTR NETWORK. Doi: 10.1158/1538-7445.AM2020-1315 [Poster]
Web of Science FullText FullText_MUG

 

** Suppan, C; Zhou, Q; Graf, R; Klocker, V; Terbuch, A; Dandachi, N; Heitzer, E; Balic, M Liquid biopsy-based detection of PIK3Ca mutations in HR positive metastastic breast cancer patients.
ANN ONCOL. 2020; 31: S41-S41.-ESMO Breast Cancer Virtual Meeting; MAY 23-24, 2020; ELECTR NETWORK. Doi: 10.1016/j.annonc.2020.03.213 [Poster] [OPEN ACCESS]
Web of Science FullText FullText_MUG

 

2019

Full paper/article (Journal)

** Ulz, P; Perakis, S; Zhou, Q; Moser, T; Belic, J; Lazzeri, I; Wölfler, A; Zebisch, A; Gerger, A; Pristauz, G; Petru, E; White, B; Roberts, CES; John, JS; Schimek, MG; Geigl, JB; Bauernhofer, T; Sill, H; Bock, C; Heitzer, E; Speicher, MR Inference of transcription factor binding from cell-free DNA enables tumor subtype prediction and early detection.
Nat Commun. 2019; 10(1): 4666-4666. Doi: 10.1038/s41467-019-12714-4 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

2018

Full paper/article (Journal)

** Zhou, Q; Eldakhakhny, S; Conforti, F; Crosbie, EJ; Melino, G; Sayan, BS Pir2/Rnf144b is a potential endometrial cancer biomarker that promotes cell proliferation.
Cell Death Dis. 2018; 9(5):504-504 Doi: 10.1038/s41419-018-0521-1 [OPEN ACCESS]
Web of Science PubMed PUBMED Central FullText FullText_MUG

 

Review

** Zhou, Q; Moser, T; Perakis, S; Heitzer, E Untargeted profiling of cell-free circulating DNA
TRANSL CANCER RES. 2018; 7: S140-S152. Doi: 10.21037/tcr.2017.10.11
Web of Science FullText FullText_MUG

 

2017

Short report/Letter

** Moser, T; Ulz, P; Zhou, Q; Perakis, S; Geigl, JB; Speicher, MR; Heitzer, E Single-Stranded DNA Library Preparation Does Not Preferentially Enrich Circulating Tumor DNA.
Clin Chem. 2017; 63(10):1656-1659 Doi: 10.1373/clinchem.2017.277988 [OPEN ACCESS]
Web of Science PubMed FullText FullText_MUG

 

© Med Uni GrazImprint